Evidence map›Paper›PMID 40248584›Full record

ArticleMedecine tropicale et sante internationale2025

[Profile of mpox cases identified during surveillance of the Kokolo health zone in Kinshasa (DRC) from August to November 2024].

Levis Amisi Kengea, Blanche Ihekambangu Ngwakaha, Winnie Masamba Bikoki, Vally Ndumbi Temuangudi, Jean Claude Nsinga Bungiena, Jean-Jacques Kape Kalume, Anthony Mbuyi Mutombe, Angèle Wumba Mavinga

Abstract readEnglish Abstract
In one paragraph

Article in Medecine tropicale et sante internationale, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Levis Amisi KengeaZone de santé Kokolo, Corps de santé militaire, Forces armées de la République démocratique du Congo.
Blanche Ihekambangu NgwakahaHôpital militaire central, Corps de santé militaire, Forces armées de la République démocratique du Congo.
Winnie Masamba BikokiHôpital militaire central, Corps de santé militaire, Forces armées de la République démocratique du Congo.
Vally Ndumbi TemuangudiCentre médical opérationnel de type A de la 113ème base aérienne de Ndolo, Corps de santé militaire, Forces armées de la République démocratique du Congo, République démocratique du Congo.
Jean Claude Nsinga BungienaCorps de santé militaire, Forces armées de la République démocratique du Congo.
Jean-Jacques Kape KalumeCorps de santé militaire, Forces armées de la République démocratique du Congo.
Anthony Mbuyi MutombeCorps de santé militaire, Forces armées de la République démocratique du Congo.
Angèle Wumba MavingaCorps de santé militaire, Forces armées de la République démocratique du Congo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The Kokolo military health zone in the city of Kinshasa (DRC) is one of the areas affected by mpox, with the presence of two subclades Ia and Ib of the monkeypox virus. This study presents the results of mpox-related surveillance activities in this area. Methods: Descriptive study of data reported by the surveillance system on the mpox epidemic in the Kokolo health zone between August and November 2024. Results: Of 202 specimens (143 males, sex ratio 0.71) from individuals clinically suspected of having mpox or contacts of known cases, 25.2% were positive by PCR at the National Institute for Biomedical Research laboratory (median age 25 years, IQR 11-31). Subjects aged 18 years and older were most affected, i.e. 41/51 (80%). Of these 51 confirmed cases, 13 (26%) and 10 (20%) were from the Kokolo 2 health areas and the Kokolo camp logistics base, respectively. All confirmed cases presented with rash. Other reported symptoms were myalgia (50/51, 98%), genital rash (42/51, 82%), arthralgia (42/51, 82%), and headache (41/51, 80%). The median length of stay at the mpox treatment center was 10 days (IQR: 7-9). Conclusions: This study showed that of 202 tests performed on persons suspected of having mpox or contacts of known cases, 25.2% were positive by PCR. All confirmed cases presented with rash, with other common symptoms including myalgia, genital rash, arthralgia, and headache. These results underscore the need to strengthen surveillance and control measures for the spread of mpox, particularly in the most affected health care settings.

Indexed as

Mpox, MonkeypoxAdolescentAdultChildDemocratic Republic of the CongoFemaleHumansMaleMiddle AgedPopulation SurveillanceTime FactorsYoung AdultDemocratic Republic of the CongoKinshasaKokoloMpoxSub-Saharan AfricaSurveillance

Identifiers

PMID40248584
PMCPMC12001985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.